RADL3.SA

RADL3.SA maintains a price-to-book ratio of 4.52 and a debt-to-equity ratio of 1.22, indicating a moderate level of leverage and a relatively high valuation compared to its book value. The company's liquidity position is characterized by a current ratio of 1.46, suggesting it has sufficient short-term assets to cover its short-term liabilities, although its cash and equivalents amount to only 287.39 million BRL, which is significantly lower than its long-term debt of 8.97 billion BRL. In terms of profitability, RADL3.SA reports a return on equity of 17.71% and a return on assets of 5.15%, which are key indicators of its efficiency in generating profits from shareholders' equity and total assets, respectively. These figures suggest that the company is effectively utilizing its equity but has room for improvement in asset utilization to enhance overall profitability. The company's revenue is concentrated in the drug retailing segment, with no significant diversification into other geographic regions or business lines. This concentration may expose the company to specific market risks, such as changes in consumer behavior or regulatory shifts within the drug retailing industry. RADL3.SA's growth trajectory is reflected in its operating cash flow of 2.43 billion BRL and free cash flow of 1.32 billion BRL, indicating strong cash generation capabilities. However, the company's capital expenditure of -1.4 billion BRL suggests a reduction in investment in long-term assets, which could impact future growth potential. The risk assessment for RADL3.SA highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to meet short-term obligations without additional financing. The dilution risk is considered low, with no immediate pressure for share issuance, and the company's capital structure remains stable with a low probability of dilution in the near term. Recent events and filings indicate that analysts have a generally positive outlook on RADL3.SA, with a mean price target of 28.75 BRL and a median price target of 28.00 BRL. The mean recommendation of 2.17 suggests a slight bias towards a buy rating, with 8 buy recommendations and 3 hold recommendations, indicating a cautious optimism among analysts.